The RSA Group was pleased to partner with ASLAN Pharmaceuticals to secure the appointment of Robert E. Hoffman as Independent Director.
Mr. Hoffman brings a strong track record in financial and operational leadership in US-listed biotech companies and is currently the Chief Financial Officer and SVP Finance of Heron Therapeutics. With his wealth of experience in financial and investor relations in the oncology biotech space, he will be an asset to the ASLAN board.
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Shawn O’Connor, Partner, The RSA Group said, “ ASLAN Pharmaceuticals is an exciting company, and we are so pleased to help bring Robert onto the board.”
Read the full press release here: http://aslanpharma.com/app/uploads/2018/10/181030-Press-Release-Board-Changes-EN.pdf